Premium
Expression of the tumour‐suppressor maspin in temporal bone carcinoma
Author(s) -
Marioni Gino,
Zanoletti Elisabetta,
Stritoni Paola,
Lionello Marco,
Giacomelli Luciano,
Gianatti Andrea,
Cattaneo Laura,
Blandamura Stella,
Mazzoni Antonio,
Martini Alessandro
Publication year - 2013
Publication title -
histopathology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.626
H-Index - 124
eISSN - 1365-2559
pISSN - 0309-0167
DOI - 10.1111/his.12151
Subject(s) - maspin , malignancy , medicine , pathological , oncology , lymph node , carcinoma , disease , pathology , cancer research , cancer , metastasis
Aims Although it accounts for fewer than 0.2% of all head and neck tumours, temporal bone squamous cell carcinoma ( SCC ) is an aggressive malignancy with a poor prognosis in advanced cases. Novel therapeutic strategies should be developed focusing on specific targeted therapies. Maspin is a serpin showing tumour‐suppressing activity which has therapeutic potential. The present study is the first to investigate maspin expression in temporal bone SCC s, using a series of 29 cases. Methods and results Cytoplasmic maspin expression was significantly higher in the group of patients whose SCC did not recur than in the group experiencing recurrences ( P = 0.029), and in G1–G2 SCC s than in G3 cases ( P = 0.001). cT correlated with recurrence rate ( P = 0.05), disease‐free survival ( DFS ) ( P = 0.008) and disease‐specific survival ( DSS ) ( P = 0.0043), and pT and pathological regional lymph node status correlated with recurrence rate ( P = 0.008 and P = 0.03, respectively), DFS ( P = 0.017 and P = 0.0049, respectively) and DSS ( P = 0.008 and P = 0.0009, respectively). Conclusions Although further studies using larger series are required, our preliminary findings suggest that cytoplasmic maspin expression has promise as a prognostic indicator of disease recurrence in temporal bone SCC , and that reactivating maspin functions in association with apoptosis‐inducing or anti‐angiogenic chemotherapeutic agents might be an important goal in the treatment of temporal bone SCC .